Models May Help in Weighing Risks of Rituximab’s Long-term Use in AAV

Models May Help in Weighing Risks of Rituximab’s Long-term Use in AAV

285584

Models May Help in Weighing Risks of Rituximab’s Long-term Use in AAV

New statistical models could help to predict the risk of relapse and infection following ongoing rituximab treatment in people with ANCA-associated vasculitis (AAV), a study suggests. These models may aid in clinical decisions about the relative risks and benefits of continuing to use rituximab beyond its customary two years with these patients, according to the researchers. The models were described in the study, “Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models” published…

You must be logged in to read/download the full post.